Name | Number of supported studies | Average coverage | |
---|---|---|---|
lung | 12 studies | 25% ± 7% | |
intestine | 8 studies | 23% ± 9% | |
peripheral blood | 6 studies | 21% ± 7% | |
kidney | 6 studies | 21% ± 4% | |
uterus | 5 studies | 36% ± 9% | |
liver | 4 studies | 27% ± 13% | |
prostate | 4 studies | 27% ± 5% | |
lymph node | 4 studies | 24% ± 4% | |
breast | 4 studies | 32% ± 5% | |
pancreas | 3 studies | 34% ± 11% | |
eye | 3 studies | 31% ± 14% | |
adrenal gland | 3 studies | 30% ± 5% | |
skin | 3 studies | 27% ± 4% | |
thymus | 3 studies | 34% ± 9% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
stomach | 100% | 2689.79 | 359 / 359 | 100% | 54.05 | 286 / 286 |
esophagus | 100% | 3974.30 | 1444 / 1445 | 100% | 57.23 | 183 / 183 |
lung | 100% | 3799.17 | 577 / 578 | 100% | 64.16 | 1155 / 1155 |
breast | 100% | 3810.24 | 459 / 459 | 100% | 76.09 | 1116 / 1118 |
skin | 100% | 5464.49 | 1809 / 1809 | 100% | 63.45 | 471 / 472 |
ovary | 100% | 5321.01 | 180 / 180 | 100% | 56.98 | 429 / 430 |
intestine | 100% | 3297.62 | 966 / 966 | 100% | 61.37 | 525 / 527 |
uterus | 100% | 3681.60 | 170 / 170 | 100% | 81.13 | 457 / 459 |
bladder | 100% | 3179.48 | 21 / 21 | 99% | 70.63 | 501 / 504 |
thymus | 100% | 3118.67 | 653 / 653 | 99% | 46.17 | 601 / 605 |
prostate | 100% | 2938.84 | 245 / 245 | 99% | 50.56 | 498 / 502 |
kidney | 100% | 2871.61 | 89 / 89 | 97% | 36.14 | 871 / 901 |
brain | 97% | 1632.85 | 2550 / 2642 | 100% | 48.64 | 705 / 705 |
pancreas | 96% | 1520.50 | 316 / 328 | 99% | 43.14 | 177 / 178 |
liver | 97% | 1629.00 | 219 / 226 | 98% | 30.61 | 397 / 406 |
adrenal gland | 100% | 4909.00 | 258 / 258 | 92% | 35.36 | 211 / 230 |
adipose | 100% | 4247.93 | 1204 / 1204 | 0% | 0 | 0 / 0 |
blood vessel | 100% | 3012.89 | 1335 / 1335 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 100% | 74.28 | 29 / 29 |
spleen | 100% | 3917.92 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 72.49 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 29.25 | 1 / 1 |
peripheral blood | 100% | 4878.26 | 925 / 929 | 0% | 0 | 0 / 0 |
muscle | 99% | 1718.81 | 794 / 803 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 96% | 34.25 | 77 / 80 |
heart | 95% | 1934.58 | 815 / 861 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0035640 | Biological process | exploration behavior |
GO_1990416 | Biological process | cellular response to brain-derived neurotrophic factor stimulus |
GO_0099578 | Biological process | regulation of translation at postsynapse, modulating synaptic transmission |
GO_0014070 | Biological process | response to organic cyclic compound |
GO_0008306 | Biological process | associative learning |
GO_0000184 | Biological process | nuclear-transcribed mRNA catabolic process, nonsense-mediated decay |
GO_0000398 | Biological process | mRNA splicing, via spliceosome |
GO_0006406 | Biological process | mRNA export from nucleus |
GO_2000622 | Biological process | regulation of nuclear-transcribed mRNA catabolic process, nonsense-mediated decay |
GO_0072715 | Biological process | cellular response to selenite ion |
GO_0090394 | Biological process | negative regulation of excitatory postsynaptic potential |
GO_0045727 | Biological process | positive regulation of translation |
GO_0048701 | Biological process | embryonic cranial skeleton morphogenesis |
GO_0006364 | Biological process | rRNA processing |
GO_1904570 | Biological process | negative regulation of selenocysteine incorporation |
GO_0017148 | Biological process | negative regulation of translation |
GO_0098978 | Cellular component | glutamatergic synapse |
GO_0005730 | Cellular component | nucleolus |
GO_0016020 | Cellular component | membrane |
GO_0016607 | Cellular component | nuclear speck |
GO_0035145 | Cellular component | exon-exon junction complex |
GO_0005654 | Cellular component | nucleoplasm |
GO_0098794 | Cellular component | postsynapse |
GO_0043025 | Cellular component | neuronal cell body |
GO_0030425 | Cellular component | dendrite |
GO_0005829 | Cellular component | cytosol |
GO_0071006 | Cellular component | U2-type catalytic step 1 spliceosome |
GO_0005737 | Cellular component | cytoplasm |
GO_0071013 | Cellular component | catalytic step 2 spliceosome |
GO_0005634 | Cellular component | nucleus |
GO_0008143 | Molecular function | poly(A) binding |
GO_0003724 | Molecular function | RNA helicase activity |
GO_0043021 | Molecular function | ribonucleoprotein complex binding |
GO_0003729 | Molecular function | mRNA binding |
GO_0005524 | Molecular function | ATP binding |
GO_0003723 | Molecular function | RNA binding |
GO_0035368 | Molecular function | selenocysteine insertion sequence binding |
GO_0035613 | Molecular function | RNA stem-loop binding |
GO_0005515 | Molecular function | protein binding |
GO_0016887 | Molecular function | ATP hydrolysis activity |
Gene name | EIF4A3 |
Protein name | Eukaryotic initiation factor 4A-III (eIF-4A-III) (eIF4A-III) (EC 3.6.4.13) (ATP-dependent RNA helicase DDX48) (ATP-dependent RNA helicase eIF4A-3) (DEAD box protein 48) (Eukaryotic initiation factor 4A-like NUK-34) (Eukaryotic translation initiation factor 4A isoform 3) (Nuclear matrix protein 265) (NMP 265) (hNMP 265) [Cleaved into: Eukaryotic initiation factor 4A-III, N-terminally processed] Eukaryotic initiation factor 4A-III (EC 3.6.4.13) (ATP-dependent RNA helicase DDX48) (ATP-dependent RNA helicase eIF4A-3) (DEAD box protein 48) (Eukaryotic translation initiation factor 4A isoform 3) |
Synonyms | DDX48 KIAA0111 |
Description | FUNCTION: ATP-dependent RNA helicase . Involved in pre-mRNA splicing as component of the spliceosome . Core component of the splicing-dependent multiprotein exon junction complex (EJC) deposited at splice junctions on mRNAs . The EJC is a dynamic structure consisting of core proteins and several peripheral nuclear and cytoplasmic associated factors that join the complex only transiently either during EJC assembly or during subsequent mRNA metabolism. The EJC marks the position of the exon-exon junction in the mature mRNA for the gene expression machinery and the core components remain bound to spliced mRNAs throughout all stages of mRNA metabolism thereby influencing downstream processes including nuclear mRNA export, subcellular mRNA localization, translation efficiency and nonsense-mediated mRNA decay (NMD). Its RNA-dependent ATPase and RNA-helicase activities are induced by CASC3, but abolished in presence of the MAGOH-RBM8A heterodimer, thereby trapping the ATP-bound EJC core onto spliced mRNA in a stable conformation. The inhibition of ATPase activity by the MAGOH-RBM8A heterodimer increases the RNA-binding affinity of the EJC. Involved in translational enhancement of spliced mRNAs after formation of the 80S ribosome complex. Binds spliced mRNA in sequence-independent manner, 20-24 nucleotides upstream of mRNA exon-exon junctions. Shows higher affinity for single-stranded RNA in an ATP-bound core EJC complex than after the ATP is hydrolyzed. Involved in the splicing modulation of BCL2L1/Bcl-X (and probably other apoptotic genes); specifically inhibits formation of proapoptotic isoforms such as Bcl-X(S); the function is different from the established EJC assembly . Involved in craniofacial development . . |
Accessions | P38919 ENST00000647795.1 ENST00000707787.1 I3L3H2 ENST00000649764.2 ENST00000707791.1 ENST00000576547.2 |